(Q35582108)

9 August 2017

1 reference

title

Cholinesterase inhibitors in non-Alzheimer dementias (English)

1 reference

9 August 2017

Cholinesterase Inhibitors in Non-Alzheimer Dementias (English)

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

31 March 2024

0 references

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

31 March 2024

2

Jeffrey L Cummings

1 reference

9 August 2017

Andrew R. Gustavson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14613594

31 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14613594

31 March 2024

publication date

1 November 2003

1 reference

Journal of the American Medical Directors Association

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

6 Suppl

1 reference

9 August 2017

page(s)

S165-9

1 reference

Physostigmine: Improvement of Long-Term Memory Processes in Normal Humans

9 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil and flight simulator performance: effects on retention of complex skills

31 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Cholinergic modulation of cognitive function in healthy subjects: acute effects of donepezil, a cholinesterase inhibitor

31 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

31 March 2024

“Mini-mental state”

6

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Cholinergic therapy for Down's syndrome

31 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Down syndrome and Alzheimer disease: response to donepezil

31 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Disordered mind and brain: the neural basis of mental symptoms.

31 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

31 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Freezing of gait in PD: prospective assessment in the DATATOP cohort

31 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

31 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

31 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

31 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

31 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

31 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients

31 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil for behavioural disorders associated with Lewy bodies: a case series

31 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

31 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil for dementia with Lewy bodies: a case study

31 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Dementia with Lewy bodies: response of delirium-like features to donepezil.

31 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil for the treatment of psychosis in dementia with Lewy bodies

31 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial

31 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

31 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil for Huntington's disease

31 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury

31 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

31 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain.

31 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia

31 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia

31 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments

31 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil improves symptoms of delirium in dementia: implications for future research

31 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil in treatment-resistant bipolar disorder.

31 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Treatment of REM sleep behavior disorder with donepezil: a report of three cases

31 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

The effects of an orally administered cholinergic agonist on REM sleep in major depression

31 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Donepezil for Tourette's disorder and ADHD

31 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Treatment of tardive dyskinesia with donepezil: a pilot study.

31 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

Open-label study of donepezil in chronic poststroke aphasia

31 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.JAM.0000095367.55043.B5

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference